Xianjian Technology (01302.HK) is the world's leading supplier of minimally invasive interventional medical devices for the treatment of cardiovascular, cerebrovascular and peripheral vascular diseases, integrating R&D, manufacturing and sales. Xianjian Technology was founded in 1999 and is headquartered in Shenzhen, China. It has a leading position in the global congenital heart disease occluder market, and is also the second largest supplier of congenital heart disease blockers in the world. Xianjian Technology has established a number of subsidiaries and sales offices in the Netherlands, France, Slovakia, Russia, India, Beijing, Shanghai, Guangzhou, Shenzhen, and Hong Kong, China. In November 2011, Xianjian Technology was successfully listed on the Hong Kong Stock Exchange, and successfully transferred from the GEM to the main board of the Hong Kong Stock Exchange in November 2013. In October 2012, Medtronic signed a strategic investment agreement with Xianjian Technology, and completed the strategic investment in Xianjian Technology in January 2013. Xianjian Technology has an experienced and highly qualified R&D team, focusing on the research and development of innovative cardiovascular interventional medical devices and related technologies. It has carried out extensive cooperation and exchanges with famous doctors and technical experts at home and abroad, and has also undertaken more than 40 government research projects. It is a national high-tech enterprise and a national postdoctoral research workstation. Xianjian Technology products are sold to 78 countries around the world, with more than 140 distributors covering Europe, South America, Asia, Africa, etc., and is the largest supplier of congenital heart disease blockers in the BRICS countries. Xianjian Technology has always been committed to independently innovating and developing cutting-edge cardiovascular interventional medical devices, and will continue to make outstanding contributions to the development of the global medical industry.